These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 20493689)

  • 1. Synthesis and evaluation of novel alpha-amino cyclic boronates as inhibitors of HCV NS3 protease.
    Li X; Zhang YK; Liu Y; Ding CZ; Li Q; Zhou Y; Plattner JJ; Baker SJ; Qian X; Fan D; Liao L; Ni ZJ; White GV; Mordaunt JE; Lazarides LX; Slater MJ; Jarvest RL; Thommes P; Ellis M; Edge CM; Hubbard JA; Somers D; Rowland P; Nassau P; McDowell B; Skarzynski TJ; Kazmierski WM; Grimes RM; Wright LL; Smith GK; Zou W; Wright J; Pennicott LE
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3550-6. PubMed ID: 20493689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel macrocyclic HCV NS3 protease inhibitors derived from α-amino cyclic boronates.
    Li X; Zhang YK; Liu Y; Ding CZ; Zhou Y; Li Q; Plattner JJ; Baker SJ; Zhang S; Kazmierski WM; Wright LL; Smith GK; Grimes RM; Crosby RM; Creech KL; Carballo LH; Slater MJ; Jarvest RL; Thommes P; Hubbard JA; Convery MA; Nassau PM; McDowell W; Skarzynski TJ; Qian X; Fan D; Liao L; Ni ZJ; Pennicott LE; Zou W; Wright J
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5695-700. PubMed ID: 20801653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent inhibitors of HCV-NS3 protease derived from boronic acids.
    Venkatraman S; Wu W; Prongay A; Girijavallabhan V; George Njoroge F
    Bioorg Med Chem Lett; 2009 Jan; 19(1):180-3. PubMed ID: 19022670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G; Sandström A; Akerblom E; Danielson UH
    Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease.
    Li X; Zhang YK; Liu Y; Zhang S; Ding CZ; Zhou Y; Plattner JJ; Baker SJ; Liu L; Bu W; Kazmierski WM; Wright LL; Smith GK; Jarvest RL; Duan M; Ji JJ; Cooper JP; Tallant MD; Crosby RM; Creech K; Ni ZJ; Zou W; Wright J
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7493-7. PubMed ID: 21041080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors.
    Boloor A; Hanway D; Joshi M; Winn DT; Mendez G; Walls M; Wei P; Qian F; Zhang X; Zhang Y; Hepperle ME; Li X; Campbell DA; Betancort JM
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5708-11. PubMed ID: 19713109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computer based design, synthesis and biological evaluation of novel indole derivatives as HCV NS3-4A serine protease inhibitors.
    Ismail NS; El Dine RS; Hattori M; Takahashi K; Ihara M
    Bioorg Med Chem; 2008 Sep; 16(17):7877-87. PubMed ID: 18752958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.
    Johansson PO; Bäck M; Kvarnström I; Jansson K; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
    Bioorg Med Chem; 2006 Aug; 14(15):5136-51. PubMed ID: 16675222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
    Venkatraman S; Njoroge FG; Girijavallabhan VM; Madison VS; Yao NH; Prongay AJ; Butkiewicz N; Pichardo J
    J Med Chem; 2005 Aug; 48(16):5088-91. PubMed ID: 16078825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques.
    Wei HY; Lu CS; Lin TH
    J Mol Graph Model; 2008 Apr; 26(7):1131-44. PubMed ID: 18024210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
    Tsantrizos YS
    Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and biological activity of m-tyrosine-based 16- and 17-membered macrocyclic inhibitors of hepatitis C virus NS3 serine protease.
    Chen KX; Njoroge FG; Pichardo J; Prongay A; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
    J Med Chem; 2005 Oct; 48(20):6229-35. PubMed ID: 16190750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P1 Phenethyl peptide boronic acid inhibitors of HCV NS3 protease.
    Priestley ES; De Lucca I; Ghavimi B; Erickson-Viitanen S; Decicco CP
    Bioorg Med Chem Lett; 2002 Nov; 12(21):3199-202. PubMed ID: 12372533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization.
    Perni RB; Pitlik J; Britt SD; Court JJ; Courtney LF; Deininger DD; Farmer LJ; Gates CA; Harbeson SL; Levin RB; Lin C; Lin K; Moon YC; Luong YP; O'Malley ET; Rao BG; Thomson JA; Tung RD; Van Drie JH; Wei Y
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1441-6. PubMed ID: 15006379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depeptidization efforts on P3-P2' alpha-ketoamide inhibitors of HCV NS3-4A serine protease: effect on HCV replicon activity.
    Bogen SL; Ruan S; Liu R; Agrawal S; Pichardo J; Prongay A; Baroudy B; Saksena AK; Girijavallabhan V; Njoroge FG
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1621-7. PubMed ID: 16387495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel azapeptide inhibitors of hepatitis C virus serine protease.
    Bailey MD; Halmos T; Goudreau N; Lescop E; Llinàs-Brunet M
    J Med Chem; 2004 Jul; 47(15):3788-99. PubMed ID: 15239657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent triazolyl-proline-based inhibitors of HCV NS3 protease.
    Naud J; Lemke C; Goudreau N; Beaulieu E; White PD; Llinàs-Brunet M; Forgione P
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3400-4. PubMed ID: 18448339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of glycine alpha-ketoamide HCV NS3 protease inhibitors: effect of carboxylic acid isosteres.
    Han W; Jiang X; Hu Z; Wasserman ZR; Decicco CP
    Bioorg Med Chem Lett; 2005 Aug; 15(15):3487-90. PubMed ID: 15982872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.
    Lampa A; Ehrenberg AE; Gustafsson SS; Vema A; Kerblom E; Lindeberg G; Karlén A; Danielson UH; Sandström A
    Bioorg Med Chem; 2010 Jul; 18(14):5413-24. PubMed ID: 20541424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel potent macrocyclic inhibitors of the hepatitis C virus NS3 protease: use of cyclopentane and cyclopentene P2-motifs.
    Bäck M; Johansson PO; Wångsell F; Thorstensson F; Kvarnström I; Ayesa S; Wähling H; Pelcman M; Jansson K; Lindström S; Wallberg H; Classon B; Rydergård C; Vrang L; Hamelink E; Hallberg A; Rosenquist S; Samuelsson B
    Bioorg Med Chem; 2007 Nov; 15(22):7184-202. PubMed ID: 17845856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.